BLISSGVS vs PGHL: Stock Comparison

Bliss GVS Pharma Limited vs Procter & Gamble Health Limited

Live data: 2 July 2026, 4:08 PM IST • Source: NSE and company filings

Procter & Gamble Health Limited is the larger company by market capitalisation. Bliss GVS Pharma Limited shows faster revenue growth, while Procter & Gamble Health Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Bliss GVS Pharma Limited and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BLISSGVS is more favourable on 4 of 13 scored metrics and PGHL on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PGHL is the larger company
₹11,172 Cr vs ₹4,782 Cr
P/E Ratio
PGHL has a lower P/E
34.28x vs 38.27x
P/B Ratio
BLISSGVS has a lower P/B
4.14x vs 21.36x
EPS
PGHL has higher earnings per share
₹196.64 vs ₹11.99
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0.19%
Revenue Growth (TTM YoY)
BLISSGVS has faster revenue growth
29.8% vs 19.1%
EPS Growth (TTM YoY)
BLISSGVS has faster EPS growth
124.7% vs 54.6%
Qtr Sales Growth
PGHL has stronger quarterly sales growth
19.1% vs 13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBLISSGVSPGHL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBLISSGVSPGHL
Live Price₹527.1₹6,737
Day Change0.68%-0.63%
Volume3.93 L4,611
52-Week High₹553₹6,975
52-Week Low₹118₹4,707
Distance from 52W High-4.68%-3.41%

Valuation

MetricBLISSGVSPGHL
Market Cap₹4,782 Cr₹11,172 Cr
P/E Ratio38.27x34.28x
P/B Ratio4.14x21.36x
EPS₹11.99₹196.64
Book Value₹107.21₹316.01
Dividend Yield0.19%2.34%

Growth

MetricBLISSGVSPGHL
Revenue Growth (TTM YoY)29.8%19.1%
EPS Growth (TTM YoY)124.7%54.6%
Qtr Sales Growth13%19.1%
Qtr Profit Growth108%54.6%

Profitability & Leverage

MetricBLISSGVSPGHL
ROE0%61.6%
ROCE11.7%83.5%
Net Margin13.93%23.22%
Operating Margin12.82%32.4%
Debt to Equity1.77x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricBLISSGVSPGHL
Promoter Holding35.36%0%
FII Holding10.45% 4.09 pp6.33% 0.13 pp
DII Holding5.04% 0.74 pp12.44% 1.23 pp
Public Holding49.15% 4.83 pp29.42% 1.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Bliss GVS Pharma Limited and Procter & Gamble Health Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.